tbuckley/cabot-search huggingface dataset:
成人急性骨髄性白血病(AML)における末梢血液のWTI遺伝子mRNA検出の予後影響 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Miyawaki S, Hatsumi N, Tamaki T, Naoe T, Ozawa K, Kitamura K, Karasuno T, Mitani K, Kodera Y, Yamagami T, Koga D
Journal: Blood (2005)
IL-33 promotes anemia during chronic inflammation by inhibiting differentiation of erythroid progenitors
Authors: James W. Swann, Lada A. Koneva, Daniel Regan-Komito, Stephen N. Sansom, Fiona Powrie, Thibault Griseri
Journal: The Journal of Experimental Medicine (2020)

An important comorbidity of chronic inflammation is anemia, which may be related to dysregulated activity of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow (BM). Among HSPCs, we found that the receptor for IL-33, ST2, is expressed preferentially and highly on erythroid progenitors. Induction of inflammatory spondyloarthritis in mice increased IL-33 in BM plasma, and IL-33 was required for inflammation-dependent suppression of erythropoiesis in BM. Conversely, administration of IL-33 in healthy mice suppressed erythropoiesis, decreased hemoglobin expression, and caused anemia. Using purified erythroid progenitors in vitro, we show that IL-33 directly inhibited terminal maturation. This effect was dependent on NF-κB activation and associated with altered signaling events downstream of the erythropoietin receptor. Accordingly, IL-33 also suppressed erythropoietin-accelerated erythropoiesis in vivo. These results reveal a role for IL-33 in pathogenesis of anemia during inflammatory disease and define a new target for its treatment.
RNAi-mediated control of CRISPR functions
Authors: Xinbo Huang, Zhicong Chen, Yuchen Liu
Journal: Theranostics (2020)

CRISPR-Cas9 has become a versatile tool for genome editing and regulation, and strategies to effectively control its activity have attracted much attention.RNAi, also a gene-regulating tool, is used as another mechanism by which eukaryotes resist the invasion of foreign genetic material.Methods: In this study, we analyzed the quantitative inhibition of the CRISPR system by using artificial miRNAs (amiRNAs) combined with the RNAi enhancer enoxacin to improve the targeting specificity of the CRISPR system.Furthermore, we examined the feasibility of improving the efficiency of gene editing and regulation by blocking the effects of natural intracellular miRNAs on sgRNAs.Results: amiRNAs targeting the sgRNA were used to control its expression, and the small molecule drug denoxacin was utilized to enhance this effect, especially in the presence of Cas9.amiRNA/enoxacin inhibited CRISPR-mediated gene editing and regulation both in vitro and in vivo and could tune sgRNA-targeting specificity.Furthermore, CRISPR efficiency was increased by blocking the effects of endogenous miRNAs. Conclusion:Our study provides an efficient molecular switch for conditional regulation of CRISPR activities in mammalian cells and also presents potentially useful approaches for solving current key issues of off-target effects and low targeting efficiency.
146P Safety and metabolic effects of fasting-mimicking diet in breast cancer patients
Authors: C. Vernieri, A. Raimondi, F. Ligorio, E. Zattarin, F. Nichetti, S. Manglaviti, G.V. Bianchi, G. Capri, L. Rivoltini, F.G.M. De Braud
Journal: Annals of Oncology (2020)
EULAR PsA management recommendations 2019: can the recommendations be improved?
Authors: Roy M Fleischmann
Journal: Annals of the Rheumatic Diseases (2020)

The European League Against Rheumatism (EULAR) has published recommendations for the treatment of psoriatic arthritis (PsA) which have been updated twice to remain timely, responding to the rapid advances in the discovery of new compounds, effective treatment strategies and evolving information on safety.1–3 Each recommendation has been supported by a systematic literature review (SLR) which formed the basis for the recommendations.4–6 Each version has had important additions and deletions; the recommendations have been increasingly useful to many stakeholders in the rheumatology community.

The American College of Rheumatology/National Psoriasis Foundation (ACR/NPF) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), an international network of rheumatologists, dermatologists, radiologists, geneticists, methodologists, epidemiologists and patient research partners, have also provided direction.7–9 

The strengths of the EULAR recommendations are many-fold. The recommendations have been updated to reflect new developments in treatment strategies, including efficacy and safety. Multiple experts are involved, including rheumatologists representing most European countries, patients with PsA, health professionals and a dermatologist, which allows for a wide breadth of expertise to form the recommendations. Importantly, the recommendations are based primarily on evidence from the SLR, but gives latitude for the experts to use their long-standing PsA disease experience and its treatment in developing the recommendations, not constrained by yes or no pairwise comparisons as is required by the processes used by ACR/NPF and GRAPPA.10–14 

EULAR and GRAPPA use ‘recommendation’ rather than ‘guideline’, a description used by ACR/NPF. A ‘recommendation’ is a suggestion of the best course of action in a situation, while a ‘guideline’ provides broad advice in following a process but does not provide precise requirements. The difference is subtle but important; a recommendation is less restrictive compared with a guideline and provides greater flexibility.

EULAR, ACR/NPF and GRAPPA have followed different processes, with …
Homocystinuria Due to Cystathionine Synthase Deficiency
Authors: Leonard Laster, George L. Spaeth, S. Harvey Mudd, James D. Finkelstein
Journal: Annals of Internal Medicine (2020)

Excerpt Dr. Leonard Laster: In 1962, Carson and Neill (1) reported results of a survey in which samples of urine from 2,081 mentally retarded individuals in Northern Ireland were examined by quali...
Abstract 12022: Telomere Length, Telomerase Activity and Vascular Aging in Patients With Type 2 Diabetes Mellitus
Authors: Natalia Brailova, Ekaterina Dudinskaya, Valentina Pykhtina, Ekaterina Plochova, Irina Strazhesko, Dariga Akasheva, Olga Tkacheva, Sergey Boytsov, Marina Shestakova
Journal: Circulation (2015)

Introduction: Type 2 diabetes mellitus (T2DM) contribute to vascular aging. The telomere length (TL) and telomerase activity (TA) are considered as biomarkers of cellular aging. TL and TA are insufficiently studied in diabetic patients. Hypothesis: Telomere biology is associated with vascular aging in diabetic patients. Methods: The study group included 50 patients with T2DM (mean age 58.4±7.83 years) and 139 healthy patients (mean age 57.45±8.14 years). All subjects were measured for TL and TA by quantitative polymerase chain reaction; oxidative stress marked by malondialdehyde (MDA); inflammation marked by C-reactive protein (CRP); arterial stiffness evaluated by pulse wave velocity (PWV); carotid intima-media thickness (IMT), plaque presence (PP) and endothelial dysfunction evaluated by flow-mediated endothelium-dependent vasodilation (FMV). Results: All patients were divided into 4 groups by the median of TL (9.75): «short» telomeres (T2DM+ (n=15) and T2DM- (n=63) and «long» telomeres (T2DM+ (n=35) and T2DM- (n=76)). Patients with T2DM and «long» TL had the state of vessels, oxidative stress, inflammation, TA as similar as in healthy people: PWV 11.54±3.57 (T2DM+) vs 10.98±1.83 m/s (T2DM-) ((=0.58), IMT 0.83±0.13 vs 0.76±0.16 mm (=0.13), PP 1.36±0.33 vs 1.23±0.20 (=0.79); MDA 2.81±0.78 vs 3.24±0.78 mkmol/l (=0.08); CRP 3.59±0.58 vs 3.66±0.50 mg/l (=0.93); TA 0.51±0.09 vs 0.60±0.05 (p=0.36). FMV was higher in diabetic patients: 11.87±3.36 vs 10.18±2.79 % (=0.049). In contrast patients with «short» TL and T2DM had more pronounced vascular aging, inflammation and lower TA than healthy people: PWV 13.48±3.24 vs 11.59±2.03 m/s (=0.003), IMT 0.95±0.17 vs 0.78±0.14 mm (&lt;0.001), PP 2.23±0.27 vs 1.38±0.17 (=0.006), FMV 8.51±3.20 vs 11.04±3.01% (=0.0002; CRP 7.39±1.47 vs 4.03±0.62 mg/l (=0.046); TA 0.47±0.08 vs 0.62±0.07 (p=0.06). Conclusion: In patients with short telomeres and T2DM signs of vascular aging, chronic inflammation and cellular aging were more pronounced than in healthy people. In contrast, in patients with long telomeres and T2DM vascular changes, oxidative stress, chronic inflammation and TA were as similar as in healthy people. Perhaps long telomeres protect patients with T2DM from accelerated vascular aging.
A Novel, Highly Selective IRAK1 Inhibitor Jh-X-119-01 Shows Synergistic Tumor Cell Killing with Ibrutinib in MYD88 Mutated B-Cell Lymphoma Cells
Authors: Guang Yang, John Hatcher, Jinhua Wang, Xia Liu, Manit Munshi, Jiaji Chen, Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Gloria Chan, Zachary Hunter, Christopher Patterson, Joshua Gustine, Jorge J. Castillo, Nathanael Gray, Steven P Treon, Sara Buhrlage
Journal: Blood (2017)
5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i)
Authors: O. Martínez-Sáez, T. Pascual, F. Brasó-Maristany, N. Chic, B. González-Farré, E. Sanfeliu, A. Rodríguez, D. Martínez, P. Galván, A. Rodriguez Hernandez, F. Schettini, B. Conte, M.J. Vidal, B. Adamo, M. Muñoz, R. Moreno, E.M. Ciruelos, I. Faull, J. Odegaard, A. Prat
Journal: Annals of Oncology (2020)
Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens
Authors: Catia Cilloniz, Cristina Dominedo, Héctor José Peroni, Pierluigi Di Giannatale, Carolina Garcia-Vidal, Albert Gabarrus, Adamanthia Liapikou, Adrian Ceccato, Antoni Torres
Journal: European Respiratory Journal (2020)

<b>This study demonstrates the importance of identifying patients over 80 years old at risk of CAP due to PES pathogens in order to initiate adequate antimicrobial therapy</b>https://bit.ly/2zuWPvx
Abstract 335: Predicting Pulse Status From the ECG Signal Without Interrupting CPR
Authors: Heemun Kwok, Shiv Bhandari, Jennifer E Blackwood, Jason Coult, Peter Kudenchuk, Thomas Rea
Journal: Circulation (2019)

Objective: Currently, cardiac arrest resuscitation requires interruptions in CPR every 2 minutes to assess cardiac rhythm and pulse. A method which analyzed the ECG during CPR to predict whether or not an organized rhythm generated a pulse could help to direct care and limit CPR interruptions. We evaluated a real-time method to predict pulse status from organized rhythm ECG segments with and without CPR. Methods: The study cohort received attempted resuscitation by a metropolitan EMS system following out-of-hospital ventricular fibrillation arrest. Two-minute rhythm/pulse checks on the continuous defibrillator recordings were annotated for CPR, rhythm, and pulse status using the ECG, impedance, and accelerometer signals, the audio recording, and EMS record. Pulse was defined by the presence of a palpable pulse by EMS. Paired ECG segments with and without CPR were extracted at each rhythm/pulse check. Using organized rhythm segments from one-third of cases for training, we developed four ECG features using wavelet analysis (median power values in three frequency bands and QRS rate) and a logistic model to predict pulse status. Predictive performances of each ECG feature and the logistic model were measured by AUC in the remaining validation cases with and without CPR. Results: There were 238 cases and 911 paired segments with a median of 3 (IQR 2,5) paired segments per case. Among 319 organized rhythm segments in the validation set, AUC for pulse prediction ranged from 0.67 to 0.79 for the individual ECG features (Figure). The logistic model was more predictive than any individual feature (AUC 0.84, 95% CI 0.80-0.89, p &lt; 0.05 for each comparison). The model predicted pulse similarly regardless of CPR activity (p = 0.2). Conclusion: ECG features extracted by wavelet analysis were predictive of pulse status among organized rhythm segments with and without ongoing CPR. Further study is required to understand how pulse prediction could guide rescuer actions in real-time.
101P Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial
Authors: A. Llombart Cussac, A. Prat, J.M. Pérez-García, J. Mateos, T. Pascual, S. Escrivà-De-Romani, A. Stradella, M. Ruiz-Borrego, B. Bermejo De Las Heras, M. Keyaerts, M. Sampayo-Cordero, A. Malfettone, R. Cortés, P. Galván, J. Cortés, G. Gebhart
Journal: Annals of Oncology (2020)
Adverse Effects Associated With Use of Nevirapine in HIV Postexposure Prophylaxis for 2 Health Care Workers
Authors: B E Sha, L A Proia, H A Kessler
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endosome-triggered ion-releasing nanoparticles as therapeutics to enhance the angiogenic efficacy of human mesenchymal stem cells
Authors: Gwang-Bum Im, Euiyoung Jung, Yeong Hwan Kim, Yu-Jin Kim, Sung-Won Kim, Gun-Jae Jeong, Tae-Jin Lee, Dong-Ik Kim, Jinheung Kim, Taeghwan Hyeon, Taekyung Yu, Suk Ho Bhang
Journal: Journal of Controlled Release (2020)
Guideline‐directed medical therapy for heart failure does not exist: a non‐judgmental framework for describing the level of adherence to evidence‐based drug treatments for patients with a reduced ejection fraction
Authors: Milton Packer, Marco Metra
Journal: European Journal of Heart Failure (2020)

Numerous guideline documents have issued recommendations to clinicians concerning the treatment of chronic heart failure and a reduced ejection fraction. However, guidelines do not describe what constitutes an acceptable standard of care, and thus, practitioners who adhere to only a small fraction of the recommendations might claim that they are treating patients ‘in accordance with the guidelines’. As a result, &lt;1% of patients with heart failure are receiving all life‐prolonging treatments at trial‐proven doses. A major impediment to the widespread adoption of trial‐based treatments is a lack of any existing framework that would allow physicians to describe the adequacy of care. To address this deficiency, we propose a novel simple approach that would ask practitioners if a patient had been treated using the dosing algorithm that had been shown to be effective for each drug class. The proposed framework recognizes that all landmark survival trials in heart failure were ‘strategy trials’, i.e. the studies mandated a standardized forced‐titration treatment plan that required timely uptitration to specified target dose unless patients experienced clinically meaningful, intolerable or serious adverse events, which persisted or recurred despite adjustment of other medications. Adherence to trial‐proven regimens might be improved if physicians were asked to describe the degree to which a patient's treatment adhered to or deviated from the strategies that had been used to demonstrate the survival benefits of neurohormonal antagonists. The proposed framework should also promote practitioner self‐awareness about the lack of evidence supporting the current widespread use of subtarget doses that are non‐adherent with trial‐proven forced‐titration strategies.
159P The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts)
Authors: D. Eiger, E. de Azambuja, M. Moreau, J. Bondele, C. Sotiriou, M.A. Franzoi, M.D.R.A. Brandão, M. Rediti, X. Wang, A.H. Awada, N. Kotecki
Journal: Annals of Oncology (2020)
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Authors: Vlado Perkovic, Robert Toto, Mark E. Cooper, Johannes F.E. Mann, Julio Rosenstock, Darren K. McGuire, Steven E. Kahn, Nikolaus Marx, John H. Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Maximillian von Eynatten, Jyothis T. George, Odd Erik Johansen, Christoph Wanner
Journal: Diabetes Care (2020)

OBJECTIVE Type 2 diabetes is a leading cause of kidney failure, but few outcome trials proactively enrolled individuals with chronic kidney disease (CKD). We performed secondary analyses of cardiovascular (CV) and kidney outcomes across baseline estimated glomerular filtration rate (eGFR) categories (≥60, 45 to &amp;lt;60, 30 to &amp;lt;45, and &amp;lt;30 mL/min/1.73 m2) in Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA), a cardiorenal placebo-controlled outcome trial of the dipeptidyl peptidase 4 inhibitor linagliptin (NCT01897532). RESEARCH DESIGN AND METHODS Participants with CV disease and/or CKD were included. The primary outcome was time to first occurrence of CV death, nonfatal myocardial infarction, or nonfatal stroke (three-point major adverse CV event [3P-MACE]), with a secondary outcome of renal death, end-stage kidney disease, or sustained ≥40% decrease in eGFR from baseline. Other end points included progression of albuminuria, change in HbA1c, and adverse events (AEs) including hypoglycemia. RESULTS A total of 6,979 subjects (mean age 65.9 years; eGFR 54.6 mL/min/1.73 m2; 80.1% albuminuria) were followed for 2.2 years. Across eGFR categories, linagliptin as compared with placebo did not affect the risk for 3P-MACE (hazard ratio 1.02 [95% CI 0.89, 1.17]) or the secondary kidney outcome (1.04 [0.89, 1.22]) (interaction P values &amp;gt;0.05). Regardless of eGFR, albuminuria progression was reduced with linagliptin, as was HbA1c, without increasing risk for hypoglycemia. AEs were balanced among groups overall and across eGFR categories. CONCLUSIONS Across all GFR categories, in participants with type 2 diabetes and CKD and/or CV disease, there was no difference in risk for linagliptin versus placebo on CV and kidney events. Significant reductions in risk for albuminuria progression and HbA1c and no difference in AEs were observed.
Immunological aspects of psoriasis.
Authors: JEAN-JACQUES GUILHOU, JACQUES CLOT, JEAN MEYNADIER, HELENE LAPINSKI
Journal: British Journal of Dermatology (1976)

Sixty patients with psoriasis have been studied for quantitative estimation of serum immunoglobulin A, G and M (60 cases), immunoglobulin E (43 cases), salivary immunoglobulin A (28 cases) and anti‐IgG factors in the serum (40 cases). All the data have been statistically compared to a large control group (300 subjects). The results show an increase of the serum IgG and IgA means, an increase of salivary IgA which is correlated with the serum IgA, an increase of IgE levels in some patients and the presence of anti‐IgG activity in the serum of 45% of patients with psoriasis. All these findings are statistically significant when compared to controls. These data could be in favour of auto‐immune processes in psoriasis.
Assessment of the skin penetration properties of different vehicles for topically applied hydrocortisone
Authors: N.A. Orr, J.F. Smith, E.A. Hill
Journal: British Journal of Dermatology (1979)

Journal Article Assessment of the skin penetration properties of different vehicles for topically applied hydrocortisone Get access N.A. Orr, N.A. Orr School of Pharmacy, Sunderland Polytechnic, Galen Building, Green Terrace, Sunderland SR1 3SD Search for other works by this author on: Oxford Academic Google Scholar J.F. Smith, J.F. Smith School of Pharmacy, Sunderland Polytechnic, Galen Building, Green Terrace, Sunderland SR1 3SD Search for other works by this author on: Oxford Academic Google Scholar E.A. Hill E.A. Hill School of Pharmacy, Sunderland Polytechnic, Galen Building, Green Terrace, Sunderland SR1 3SD Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 100, Issue 6, 1 June 1979, Page 737, https://doi.org/10.1111/j.1365-2133.1979.tb08085.x Published: 01 June 1979
The potential role of RNA N6-methyladenosine in Cancer progression
Authors: Tianyi Wang, Shan Kong, Mei Tao, Shaoqing Ju
Journal: Molecular Cancer (2020)

Abstract N6-methyladenosine (m6A) is considered the most common, abundant, and conserved internal transcript modification, especially in eukaryotic messenger RNA (mRNA). m6A is installed by m6A methyltransferases (METTL3/14, WTAP, RBM15/15B, VIRMA and ZC3H13, termed “writers”), removed by demethylases (FTO, ALKBH5, and ALKBH3, termed “erasers”), and recognized by m6A-binding proteins (YTHDC1/2, YTHDF1/2/3, IGF2BP1/2/3, HNRNP, and eIF3, termed “readers”). Accumulating evidence suggests that m6A RNA methylation greatly impacts RNA metabolism and is involved in the pathogenesis of many kinds of diseases, including cancers. In this review, we focus on the physiological functions of m6A modification and its related regulators, as well as on the potential biological roles of these elements in human tumors.
Sporotrichoid phaeohyphomycosis due to Alternaria infectoria
Authors: R. Gerdsen, M. Uerlich, G.S. De Hoog, T. Bieber, R. Horré
Journal: British Journal of Dermatology (2008)

We describe a cardiac transplant patient who had human cutaneous alternariosis with a sporotrichoid distribution of skin lesions. In this patient identification of the causative organism Alternaria infectoria was achieved by sequencing the rDNA internal transcribed spacer domain. Treatment with itraconazole led to clinical resolution within 4 months.
HEREDITARY ABSENCE OF MUSCLE PHOSPHORYLASE (McCARDLE'S DISEASE)
Authors: H K BEECHER
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal